Lakefront Biotherapeutics NV (GLPGF)
GLPGF is quoted over the counter, not listed on an exchange. Lakefront Biotherapeutics NV files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | GLPGF, quoted over the counter |
| SEC CIK | 0001421876 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | 2800 Mechelen |
| Incorporated in | Belgium |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-26 |
| Cash and burn | $97.1M cash; operating cash flow -$71.1M a quarter. | Report 2025-12-31 |
| Shares outstanding | 65,897,071 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO Bedrijfsrevisoren - BDO Réviseurs d'Entreprises, Zaventem, Belgium | PCAOB Form AP 2026-04-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $1.2B | $354.6M | -$284.5M | $97.1M | No debt tags | $1.2B | 20-F 2026-03-26 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-05-08 |
| Latest annual report | 20-F | 2026-03-26 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 548 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier